TNFRSF4 and atopic eczema: In a phase 1 trial of KHK4083 enrolling 22 patients with atopic dermatitis, injection of this antibody on day 1, day 15 and day 29 ablated OX40-expressing cells and significantly attenuated the symptoms of atopic dermatitis compared to the effects of placebo [61].